Drug
Lenalidomide clinical trials
Also written Revlimid, CC-5013 and CDC 501.
- studies test it
- 818
- open now
- 111
- in phase 3
- 86
- first study started
- 2002
Keep track of what changes. Save the Lenalidomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
818 studies that test it; most in 2009 (68)
| Year | Studies |
|---|---|
| 2002 | 8 |
| 2003 | 9 |
| 2004 | 16 |
| 2005 | 29 |
| 2006 | 23 |
| 2007 | 32 |
| 2008 | 59 |
| 2009 | 68 |
| 2010 | 64 |
| 2011 | 48 |
| 2012 | 59 |
| 2013 | 32 |
| 2014 | 31 |
| 2015 | 31 |
| 2016 | 30 |
| 2017 | 31 |
| 2018 | 23 |
| 2019 | 32 |
| 2020 | 37 |
| 2021 | 24 |
| 2022 | 39 |
| 2023 | 25 |
| 2024 | 24 |
| 2025 | 26 |
| 2026 | 18 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 300
- Phase 2
- 557
- Phase 3
- 86
- Phase 4
- 15
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 44
Who runs them
Industry 146 · Other 672
National Cancer Institute (NCI) (52) · M.D. Anderson Cancer Center (50) · Celgene (46) · Mayo Clinic (24) · Celgene Corporation (22) · Memorial Sloan Kettering Cancer Center (20) · Ruijin Hospital (13) · Dana-Farber Cancer Institute (12)
Often tested with
Tested in the same studies.
Dexamethasone (199) · Rituximab (99) · Bortezomib (63) · Daratumumab (34) · Carfilzomib (34) · Cyclophosphamide (34) · Obinutuzumab (25) · Ibrutinib (24)
Studies
Open first, then newest update. How each study uses Lenalidomide is read from its arms, and is right about nine times in ten.
Testing it · 818
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Lenalidomide
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05776979Written as lenalidomide
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Lenalidomide
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingPhase 2/3AbbVieNCT07095452Written as Lenalidomide
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Revlimid (lenalidomide)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1National Cancer Institute (NCI)NCT04301076Written as Lenalidomide
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT03523975Written as Lenalidomide
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingPhase 3European Myeloma Network B.V.NCT05243797Written as Lenalidomide
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingPhase 1/2Hoffmann-La RocheNCT05583617Written as Lenalidomide
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04404088Written as Lenalidomide
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingPhase 3Intergroupe Francophone du MyelomeNCT06918002Written as Lenalidomide (Revlimid®)
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab, tafasitamab and lenalidomide
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingPhase 2Xiaohui RenNCT07839247Written as Lenalidomide
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as Lenalidomide
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Lenalidomide
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingPhase 2University of MiamiNCT06997081Written as Lenalidomide
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingPhase 2Shunda DuNCT07639138Written as Lenalidomide
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT05615636Written as Lenalidomide
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07652905Written as Lenalidomide
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07814001Written as Lenalidomide
See all 818 studies that test Lenalidomide →
Given in every arm · 179 — Lenalidomide is usual care beside what is tested
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Lenalidomide
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Lenalidomide
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as Lenalidomide
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Lenalidomide
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaRecruitingPhase 3Canadian Cancer Trials GroupNCT06182774Written as Lenalidomide
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06149286Written as Lenalidomide
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Lenalidomide
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Lenalidomide
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Lenalidomide
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT06220032Written as Lenalidomide
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as Lenalidomide
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT03937635Written as Lenalidomide
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04566328Written as Lenalidomide
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Lenalidomide
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingPhase 3AstraZenecaNCT07764978Written as Lenalidomide
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaRecruitingPhase 3Sinocelltech Ltd.NCT07562022Written as Lenalidomide
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as Lenalidomide
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07717177Written as Lenalidomide
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Lenalidomide
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Lenalidomide
Showing 20 of 179.
As the comparator · 20 — what is tested is compared with Lenalidomide
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Lenalidomide
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Lenalidomide
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07764861Written as Lenalidomide
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07753369Written as Lenalidomide Capsules
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Lenalidomide
- Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingPhase 2Irene Ghobrial, MDNCT05469893Written as Lenalidomide
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruitingPhase 1Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07697339Written as Rituximab plus lenalidomide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Lenalidomide
- Isa-VRD in TIE HRMMNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07334535Written as Bortezomib, Lenalidomide, Dexamethasone
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07189065Written as Lenalidomide
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT06082102Written as Lenalidomide
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingPhase 3BeOne MedicinesNCT05100862Written as Lenalidomide
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT06169215Written as Lenalidomide
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05827016Written as Lenalidomide
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingPhase 3PfizerNCT05317416Written as Lenalidomide
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06313996Written as Lenalidomide
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT05371093Written as Lenalidomide
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedPhase 3Millennium Pharmaceuticals, Inc.NCT01659658Written as Lenalidomide
- Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance StrategyCompletedPhase 2Arbeitsgemeinschaft medikamentoese TumortherapieNCT02891811Written as Lenalidomide
- Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT00884546Written as Lenalidomide
Codes
What other systems call Lenalidomide · ClinicalTrials.gg INT006682
- MeSH (NLM) D000077269LenalidomideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) F0P408N6V4LENALIDOMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 342369Confirmed FDA, Wikidata
- Wikidata Q425681(RS)-lenalidomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2668LenalidomideOne source FDA
- DrugBank DB00480One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077269 | Lenalidomide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | F0P408N6V4 | LENALIDOMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 342369 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425681 | (RS)-lenalidomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2668 | Lenalidomide | One source FDA |
| DrugBank | DB00480 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.